BTIG analyst Sean Lavin initiated coverage on Masimo (NASDAQ: MASI) with a Buy rating and $32.00 price target.
Lavin is optimistic on the medical technology company's future, seeing limited downside for the underperforming stock.
The analyst wrote, “We see multiple things that could move shares higher, the first two being the ones with the largest potential impact in our opinion. Hemoglobin could eventually work near perfectly and if it does we believe adoption would be brisk.
"Management could significantly reign in expenses moving operating margins meaningfully higher or an acquirer could do this. GE (BTIG Not Rated) and/or Philips (BTIG Not Rated) could fully launch hemoglobin over the next 12-24 months moving Rainbow sales upwards. The company could roll out multiple new products or one that excited investors such as non-invasive glucose monitoring (likely still a few years away). Pulse ox pricing could improve.”
BTIG emphasized the consistency of pulse ox, and the possibility for it to continue to improve. “As long as people get sick, get the flu, have surgery, develop breathing issues, etc. pulse ox will be consistently used.”
In addition, Lavin expects the hemoglobin device to improve.
Shares of Masimo are up 1.21 percent at $24.24. The firm's price target suggests a 31.85 percent premium.
See more from Benzinga
- Analysts Skeptical On Rackspace Go-Private Chatter
- Spectrum Pharmaceuticals Shares Up 5% Following FDA Accelerated Approval For Beleodaq (SPPI)
- JP Morgan: Russian Political Turmoil Weighs On SAP
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.